Idiosyncratic drug-induced liver injury (DILI) is a rare disease that develops independently of
drug dose, route, or duration of administration. Furthermore, idiosyncratic DILI is not a single …

The emergent discipline of metabolomics has attracted considerable research effort in
hepatology. Here we review the metabolomic data for non-alcoholic fatty liver disease …

Paracetamol (APAP) is one of the most widely used and popular over-the-counter analgesic
and antipyretic drugs in the world when used at therapeutic doses. APAP overdose can …

Safety attrition of drugs during preclinical development as well as in late-stage clinical trials
continues to be a challenge for the pharmaceutical industry for patient welfare and financial …

Aliment Pharmacol Ther 2011; 34: 11–20 Summary Background Drug‐induced liver injury
(DILI) is a significant cause of morbidity and mortality accounting for at least 13% of acute …

A new generation of technologies commonly named omics permits assessment of the
entirety of the components of biological systems and produces an explosion of data and a …

Drug-induced liver injury (DILI) is an adverse toxic hepatic clinical reaction associated to the
administration of a drug that can occur both at early clinical stages of drug development, as …

Acetaminophen (APAP) is a commonly used analgesic drug that can cause liver injury, liver
necrosis and liver failure. APAP-induced liver injury is associated with glutathione depletion …

The ERK/HIF-1α signaling pathway is believed to play an important role in the genesis of
progressive fibrosis. An increasing expression of HIF-1α and ERK accompanies CCl4 …

Background Idiosyncratic drug‐induced liver injury (DILI) is a complex disorder that is
difficult to predict, diagnose and treat. Aim To describe the global serum proteome of …